Table 1.
Subsequent cancer therapies
| Olaparib (n = 205) | TPC (n = 97) | |
|---|---|---|
| PARP inhibitor | 4 (2.0) | 12 (12.4) |
| Platinum-based chemotherapy | 88 (42.9) | 47 (48.5) |
| Other cytotoxic chemotherapy | 136 (66.3) | 71 (73.2) |
| Hormonal therapy | 42 (20.5) | 25 (25.8) |
| Targeted/biologics | 38 (18.5) | 24 (24.7) |
| Other | 8 (3.9) | 4 (4.1) |
| No subsequent cancer therapy | 33 (16.1) | 17 (17.5) |
| Continuing study treatmenta | 10 (4.9) | 0 |
Data are presented as n (%). Patients may have received a subsequent cancer therapy in more than one category.
a
As of DCO 17 November 2019
DCO, data cut-off; PARP, poly(ADP-ribose) polymerase; TPC, chemotherapy treatment of physician’s choice.